Cover Image
市場調查報告書

遺傳性血管水腫(HAE):開發平台分析

Hereditary Angioedema (HAE) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 200958
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
遺傳性血管水腫(HAE):開發平台分析 Hereditary Angioedema (HAE) - Pipeline Review, H1 2017
出版日期: 2017年06月27日 內容資訊: 英文 90 Pages
簡介

所謂遺傳性血管水腫(HAE)是人體組織各處(腹部、臉部等)產生許多朣塊這樣的先天性絕症。主要症狀有劇烈的腹痛及肌肉痙攣、脫水症狀、腹瀉·休克症、聲音嘶啞、吞嚥困難·呼吸困難等。主要治療法為藥物療法(Epinephrine·抗組織胺藥物·皮質類固醇其他)等。

本報告提供全球各國的遺傳性血管水腫(HAE)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查。

目錄

簡介

  • 分析範圍

遺傳性血管水腫概要

治療藥的開發

  • 遺傳性血管水腫開發中產品:概要
  • 遺傳性血管水腫開發中產品:比較分析

各企業正在開發的遺傳性血管水腫治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

遺傳性血管水腫治療藥:開發中的產品一覽(各企業)

遺傳性血管水腫開發治療藥的企業

  • Adverum Biotechnologies, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Cevec Pharmaceuticals GmbH
  • CSL Limited
  • Global Blood Therapeutics, Inc.
  • iBio, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Pharming Group N.V.
  • ProMetic Life Sciences Inc.
  • Ra Pharmaceuticals, Inc.
  • Shire Plc

遺傳性血管水腫:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

遺傳性血管水腫治療藥:開發中產品的最新趨勢

遺傳性血管水腫相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9438IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2017, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline landscape.

Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 4, 10 and 2 respectively.

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview
    • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development
    • ActiveSite Pharmaceuticals Inc
    • Adverum Biotechnologies Inc
    • Arrowhead Pharmaceuticals Inc
    • BioCryst Pharmaceuticals Inc
    • Cevec Pharmaceuticals GmbH
    • CSL Ltd
    • Global Blood Therapeutics Inc
    • iBio Inc
    • Ionis Pharmaceuticals Inc
    • Kalvista Pharmaceuticals Inc
    • Pharming Group NV
    • ProMetic Life Sciences Inc
    • Shire Plc
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drug Profiles
    • ADVM-053 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AROF-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATN-035 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATN-249 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BCX-7353 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C1 esterase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C1 esterase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C1 esterase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C1 esterase inhibitor (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C1 esterase inhibitor (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-312 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GBT-18713 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • icatibant acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IONIS-PKKLRx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IONIS-PKKRx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KVD-818 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lanadelumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHP-623 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones
    • Featured News & Press Releases
      • May 25, 2017: BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial
      • May 22, 2017: Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop
      • May 18, 2017: Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial
      • Apr 12, 2017: BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks
      • Apr 04, 2017: New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients
      • Mar 22, 2017: NEJM Publishes Pivotal Data on Preventing HAE Attacks
      • Mar 16, 2017: Shire Receives European Approval for Label Extension of CINRYZE to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Pediatric Patients with HAE
      • Mar 06, 2017: Attune Pharmaceuticals Announces Pre-Clinical Data for ATN-249, An Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at AAAAI
      • Mar 01, 2017: Attune Pharmaceuticals Announces Late-Breaking Poster Presentation of ATN-249, an Oral Kallikrein Inhibitor for the Treatment of HAE
      • Feb 27, 2017: BioCryst Reports Positive Interim Results from its APeX-1 Trial
      • Feb 23, 2017: New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease
      • Jan 16, 2017: European Commission amends Marketing Authorisation for RUCONEST to include self-administration
      • Dec 15, 2016: CHMP Adopts Extension To Existing Therapeutic Indication For Cinryze
      • Dec 01, 2016: CSL Commits to New Phase I Clinical Trials of CSL312 in Australia
      • Nov 14, 2016: Pharming Announces the Presentation of the Results of the RUCONEST Phase II study for Prophylaxis of Hereditary Angioedema Attacks
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ActiveSite Pharmaceuticals Inc, H1 2017
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Adverum Biotechnologies Inc, H1 2017
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioCryst Pharmaceuticals Inc, H1 2017
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Cevec Pharmaceuticals GmbH, H1 2017
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Ltd, H1 2017
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Global Blood Therapeutics Inc, H1 2017
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by iBio Inc, H1 2017
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Kalvista Pharmaceuticals Inc, H1 2017
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharming Group NV, H1 2017
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ProMetic Life Sciences Inc, H1 2017
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Shire Plc, H1 2017
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, H1 2017
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top